Adipose tissue dysfunction and inflammation in cardiovascular disease

Frontiers of Hormone Research

Volumn 43, Issue , 2014, Pages 79-92

  Wronkowitz, Nina ^a   Romacho, Tania ^a   Sell, Henrike ^a   Eckel, Juergen ^a  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APELIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OMENTIN; PROTEIN; UNCLASSIFIED DRUG; ACUTE PHASE PROTEIN; ADIPOCYTOKINE; APLN PROTEIN, HUMAN; CYTOKINE; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LCN2 PROTEIN, HUMAN; LECTIN; LIPOCALIN; ONCOPROTEIN; SIGNAL PEPTIDE;

ADIPO VASCULAR AXIS; ADIPOSE TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; HUMAN; NONHUMAN; OBESITY; PRIORITY JOURNAL; ADIPOCYTE; BIOSYNTHESIS; CARDIOVASCULAR DISEASES; COMPLICATION; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

ACUTE-PHASE PROTEINS; ADIPOCYTES; ADIPOKINES; ADIPOSE TISSUE; CARDIOVASCULAR DISEASES; CYTOKINES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; GPI-LINKED PROTEINS; HUMANS; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LECTINS; LIPOCALINS; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; PROTO-ONCOGENE PROTEINS; RISK FACTORS;

EID: 84908593126     PISSN: 03013073     EISSN: 16623762     Source Type: Book Series    
DOI: 10.1159/000360560     Document Type: Article

References (33)

1. Gualillo O, González-Juanatey JR, Lago F: The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med 2007; 17: 275-283.
2. Trayhurn P, Drevon CA, Eckel J: Secreted proteins from adipose tissue and skeletal muscle-adipokines, myokines and adipose/muscle cross-talk. Arch Physiol Biochem 2011; 117: 47-56.
3. Lehr S, Hartwig S, Lamers D, Famulla S, Müller S, Hanisch FG, Cuvelier C, Ruige J, Eckardt K, Ouwens DM, Sell H, Eckel J: Identification and validation of novel adipokines released from primary human adipocytes. Mol Cell Proteomics 2012; 11:M111.010504.
4. Bosello O, Zamboni M: Visceral obesity and metabolic syndrome. Obes Rev 2000; 1: 47-56.
5. Sell H, Habich C, Eckel J: Adaptive immunity in obesity and insulin resistance. Nat Rev Endocrinol 2012; 8: 709-716.
6. Greulich S, Chen WJ, Maxhera B, Rijzewijk LJ, van der Meer RW, Jonker JT, Mueller H, de Wiza DH, Floerke RR, Smiris K, Lamb HJ, de Roos A, Bax JJ, RomijnJA, Smit JW, Akhyari P, Lichtenberg A, Eckel J, Diamant M, Ouwens DM: Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies. PLoS One 2013; 8: e59697.
7. Taube A, Schlich R, Sell H, Eckardt K, Eckel J: Inflammation and metabolic dysfunction: links to cardiovascular diseases. Am J Physiol Heart Circ Physiol 2012; 302:H2148-H2165.
8. Lamers D, Famulla S, Wronkowitz N, Hartwig S, Lehr S, Ouwens DM, Eckardt K, Kaufman JM, Ryden M, Muller S, Hanisch FG, Ruige J, Arner P, Sell H, Eckel J: Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 2011; 60: 1917-1925.
9. Sell H, Blüher M, Klöting N, Schlich R, Willems M, Ruppe F, Knoefel W, Dietrich A, Arner P, Frayn K, Eckel J: Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro. Diabetes Care 2013; 36: 4083-4090.
10. Zhong J, Rao X, Rajagopalan S: An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease. Atherosclerosis 2013; 226: 305-314.
11. Fadini GP, Avogaro A: Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol 2011; 55: 10-16.
12. Ta NN, Li Y, Schuyler CA, Lopes-Virella MF, Huang Y: DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis 2010; 213: 429-435.
13. Hu Y, Liu H, Simpson RW, Dear AE: GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells. Mol Biol Rep 2013; 40: 2273-2279.
14. Shah Z, Pineda C, Kampfrath T, Maiseyeu A, Ying Z, Racoma I, Deiuliis J, Xu X, Sun Q, Moffatt-Bruce S, Villamena F, Rajagopalan S: Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vascul Pharmacol 2011; 55: 2-9.
15. Wronkowitz N, Villalobos L, Sanchez-Ferrer C, Peiro C, Sell H, Eckel J: Dipeptidyl peptidase 4 (DPP4) induces inflammation and proliferation of human smooth muscle cells by activation of the ERK-signaling pathway. Diabetes 2013; 62(suppl 1): A52.
16. Ervinna N, Mita T, Yasunari E, Azuma K, Tanaka R, Fujimura S, Sukmawati D, Nomiyama T, KanazawaA, Kawamori R, Fujitani Y, Watada H: Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endocrinology 2013; 154: 1260-1270.
17. Sanchez-Ferrer C, Vallejo S, Romacho T, Villalobos L, Wronkowitz N, Sell H, Eckel J, Peiro C: Dipeptidyl peptidase-4 impairs microvascular endothelial-dependent relaxation: the role of cyclooxygenase. Diabetes 2013; 62(suppl 1):A128.
18. Shah Z, Kampfrath T, Deiuliis JA, Zhong J, Pineda C, Ying Z, Xu X, Lu B, Moffatt-Bruce S, Durairaj R, Sun Q, Mihai G, Maiseyeu A, Rajagopalan S: Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation 2011; 124: 2338-2349.
19. Ikeda T, Kumagai E, Iwata S, Yamakawa A: Soluble CD26/dipeptidyl peptidase IV enhances the transcription of IL-6 and TNF-alpha in THP-1 cells and monocytes. PLoS One 2013; 8:e66520.
20. Wang Y: Small lipid-binding proteins in regulating endothelial and vascular functions: focusing on adipocyte fatty acid binding protein and lipocalin-2. Br J Pharmacol 2012; 165: 603-621.
21. Liu JT, Song E, Xu A, Berger T, Mak TW, Tse HF, Law IK, Huang B, Liang Y, Vanhoutte PM, Wang Y: Lipocalin-2 deficiency prevents endothelial dysfunction associated with dietary obesity: role of cytochrome P450 2C inhibition. Br J Pharmacol 2012; 165: 520-531.
22. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430.
23. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I: Retraction. Science 2007; 318: 565.
24. Revollo JR, Korner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, Milbrandt J, Kiess W, Imai S: Nampt/ PBEF/visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007; 6: 363-375.
25. Romacho T, Sánchez-Ferrer CF, Peiró C: Visfatin/ Nampt: an adipokine with cardiovascular impact. Mediators Inflamm 2013; 2013: 946427.
26. Sommer G, Garten A, Petzold S, Beck-Sickinger AG, Bluher M, Stumvoll M, Fasshauer M: Visfatin/PBEF/ Nampt: structure, regulation and potential function of a novel adipokine. Clin Sci (Lond) 2008; 115: 13-23.
27. Filippatos TD, Randeva HS, Derdemezis CS, Elisaf MS, Mikhailidis DP: Visfatin/PBEF and atherosclerosis-related diseases. Curr Vasc Pharmacol 2010; 8: 12-28.
28. Tan BK, Adya R, Randeva HS: Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med 2010; 20: 143-148.
29. Yamawaki H: Vascular effects of novel adipocytokines: focus on vascular contractility and inflammatory responses. Biol Pharm Bull 2011; 34: 307-310.
30. Moreno-Navarrete JM, Ortega F, Castro A, Sabater M, Ricart W, Fernández-Real JM: Circulating omentin as a novel biomarker of endothelial dysfunction. Obesity (Silver Spring) 2011; 19: 1552-1559.
31. Greulich S, Chen WJ, Maxhera B, Rijzewijk LJ, van der Meer RW, Jonker JT, Mueller H, de Wiza DH, Floerke RR, Smiris K, Lamb HJ, de Roos A, Bax JJ, Romijn JA, Smit JW, Akhyari P, Lichtenberg A, Eckel J, Diamant M, Ouwens DM: Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies. PLoS One 2013; 8:e59697.
32. Barnes G, Japp AG, Newby DE: Translational promise of the apelin-APJ system. Heart 2010; 96: 1011-1016.
33. Kuba K, Zhang L, Imai Y, Arab S, Chen M, Maekawa Y, Leschnik M, Leibbrandt A, Markovic M, Schwaighofer J, Beetz N, Musialek R, Neely GG, Komnenovic V, Kolm U, Metzler B, Ricci R, Hara H, Meixner A, Nghiem M, Chen X, Dawood F, Wong KM, Sarao R, Cukerman E, Kimura A, Hein L, Thalhammer J, Liu PP, Penninger JM: Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. Circ Res 2007; 101:e32-e42.